Marissa J Schafer1,2, Andrew J Haak3, Daniel J Tschumperlin3, Nathan K LeBrasseur4,5,6. 1. Robert and Arlene Kogod Center on Aging, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905, USA. 2. Department of Physical Medicine and Rehabilitation, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA. 3. Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA. 4. Robert and Arlene Kogod Center on Aging, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905, USA. lebrasseur.nathan@mayo.edu. 5. Department of Physical Medicine and Rehabilitation, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA. lebrasseur.nathan@mayo.edu. 6. Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA. lebrasseur.nathan@mayo.edu.
Abstract
PURPOSE OF THE REVIEW: Senescent cells have the capacity to both effect and limit fibrosis. Senotherapeutics target senescent cells to improve aging conditions. Here, we review the contexts in which senescent cells mediate wound healing and fibrotic pathology and the potential utility of senotherapeutic drugs for treatment of fibrotic disease. RECENT FINDINGS: Multi-action and temporal considerations influence deleterious versus beneficial actions of senescent cells. Acutely generated senescent cells can limit proliferation, and the senescence-associated secretory phenotype (SASP) contains factors that can facilitate tissue repair. Long-lived senescent cells that evade clearance or are generated outside of programmed remodeling can deplete the progenitor pool to exhaust regenerative capacity and through the SASP, stimulate continual activation, leading to disorganized tissue architecture, fibrotic damage, sterile inflammation, and induction of bystander senescence. Senescent cells contribute to fibrotic pathogenesis in multiple tissues, including the liver, kidney, and lung. Senotherapeutics may be a viable strategy for treatment of a range of fibrotic conditions.
PURPOSE OF THE REVIEW: Senescent cells have the capacity to both effect and limit fibrosis. Senotherapeutics target senescent cells to improve aging conditions. Here, we review the contexts in which senescent cells mediate wound healing and fibrotic pathology and the potential utility of senotherapeutic drugs for treatment of fibrotic disease. RECENT FINDINGS: Multi-action and temporal considerations influence deleterious versus beneficial actions of senescent cells. Acutely generated senescent cells can limit proliferation, and the senescence-associated secretory phenotype (SASP) contains factors that can facilitate tissue repair. Long-lived senescent cells that evade clearance or are generated outside of programmed remodeling can deplete the progenitor pool to exhaust regenerative capacity and through the SASP, stimulate continual activation, leading to disorganized tissue architecture, fibrotic damage, sterile inflammation, and induction of bystander senescence. Senescent cells contribute to fibrotic pathogenesis in multiple tissues, including the liver, kidney, and lung. Senotherapeutics may be a viable strategy for treatment of a range of fibrotic conditions.
Authors: Carolyn M Roos; Michael Hagler; Bin Zhang; Elise A Oehler; Arman Arghami; Jordan D Miller Journal: Am J Physiol Heart Circ Physiol Date: 2013-08-30 Impact factor: 4.733
Authors: G P Dimri; X Lee; G Basile; M Acosta; G Scott; C Roskelley; E E Medrano; M Linskens; I Rubelj; O Pereira-Smith Journal: Proc Natl Acad Sci U S A Date: 1995-09-26 Impact factor: 11.205
Authors: Erawan Borkham-Kamphorst; Christian Schaffrath; Eddy Van de Leur; Ute Haas; Lidia Tihaa; Steffen K Meurer; Yulia A Nevzorova; Christian Liedtke; Ralf Weiskirchen Journal: Biochim Biophys Acta Date: 2014-01-31
Authors: Juan Carlos Acosta; Ana Banito; Torsten Wuestefeld; Athena Georgilis; Peggy Janich; Jennifer P Morton; Dimitris Athineos; Tae-Won Kang; Felix Lasitschka; Mindaugas Andrulis; Gloria Pascual; Kelly J Morris; Sadaf Khan; Hong Jin; Gopuraja Dharmalingam; Ambrosius P Snijders; Thomas Carroll; David Capper; Catrin Pritchard; Gareth J Inman; Thomas Longerich; Owen J Sansom; Salvador Aznar Benitah; Lars Zender; Jesús Gil Journal: Nat Cell Biol Date: 2013-06-16 Impact factor: 28.824
Authors: Darren J Baker; Bennett G Childs; Matej Durik; Melinde E Wijers; Cynthia J Sieben; Jian Zhong; Rachel A Saltness; Karthik B Jeganathan; Grace Casaclang Verzosa; Abdulmohammad Pezeshki; Khashayarsha Khazaie; Jordan D Miller; Jan M van Deursen Journal: Nature Date: 2016-02-03 Impact factor: 49.962
Authors: Vivien M Hsu; Eszter Kozák; Qiaoli Li; Márta Bocskai; Naomi Schlesinger; Ann Rosenthal; Scott T McClure; László Kovács; László Bálint; Szilvia Szamosi; Gabriella Szücs; Mary Carns; Kathleen Aren; Isaac Goldberg; András Váradi; John Varga Journal: Rheumatology (Oxford) Date: 2022-03-02 Impact factor: 7.046
Authors: Varun Kumar; Raman Agrawal; Aparamita Pandey; Stefan Kopf; Manuel Hoeffgen; Serap Kaymak; Obul Reddy Bandapalli; Vera Gorbunova; Andrei Seluanov; Marcus A Mall; Stephan Herzig; Peter P Nawroth Journal: EMBO J Date: 2020-04-27 Impact factor: 11.598